Anti-Infective Pharmaceuticals Market in India 2012

About This Presentation
Title:

Anti-Infective Pharmaceuticals Market in India 2012

Description:

Bharatbook.com introduces a new report on " Anti-Infective Pharmaceuticals Market in India 2012 " it has introduced some control programmes, undertaken various Private Partnership Projects (PPP) and has taken initiatives to reduce drug prices. – PowerPoint PPT presentation

Number of Views:385

less

Transcript and Presenter's Notes

Title: Anti-Infective Pharmaceuticals Market in India 2012


1
I
Anti-Infective Pharmaceuticals Market - India
September 2011
2
Executive Summary
Anti-infective pharmaceuticals market in India is
valued at INR X bn in 20--
Market
Market is expected to grow at a CAGR of x from
20----
Anti infectives are the largest contributor to
domestic sales, contributing around y
Drivers
Challenges
Pricing pressureLogistic problems in the vaccine
market
Increasing patient population
Drivers andChallenges
Increasing number of vaccine approvalsIncrease
in health insurances
Introduction of new drugs
Phases of clinical trial
Drug regulation and patents
Approval and licensing of drugsPatents
Highly fragmented market with large number of
players
Major foreign players in the market include
Gilead inc, Abbott, Glaxosmithkline etcMajor
domestic companies include Ranbaxy, Cipla, Dr.
Reddys, Sun Pharmaceuticals, PanaceaBiotech,
Torrent Pharmaceuticals among others
Competition
Strategicrecommendations
Foray into the adult vaccine marketPartnership
with Governmental and private bodies
2
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
3
Introduction
Market Overview
Drivers Challenges
Government Initiatives
Drug Regulation and Patents
Competition
Strategic Recommendations
3
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
4
Indian anti-infectives market is expected to
witness an
enormous growth over the coming years
Indian Market - Overview
Market Size and Growth
Anti-infectives belong to the acute segment
which makes up around z of the total
pharmaceutical
INR bn
200
industry
x x6
150 x5
Anti-infectives are the largest contributor to
domesticpharmaceuticals sales, contributing
around y
x3 x4
100 x1 x2
Cephalosporins, penicillins and quinolones are
key drugclasses among anti-infectives, with a
share of around z ofthe countrys
anti-infectives market
50
0
Presently the market has a size of INR X bn,
and is expected to grow at a CAGR of x from
20-----
2010 2011e 2012e 2013e 2014e 2015e
Top pharmaceutical segments - 2010
In 2010 GSKs Augmentin was the highest selling
drug
with sales of INR Y bn
0 2 4
6 8 10 12 14 16 18
Zifi, Taxim ,Monocef, Mox, Taxim-O , Zinacef and
Gerimacwere the other top selling drugs

anti-infectives CVS
y1y2
India has emerged as one of the leading
vaccine manufacturer in recent times, producing
z of the
gastro CNS
y3y4
respiratory diabetes
y5 y6y7
global health vaccines
Pentaxim, Varivax and Prevenar were the top
sellingvaccines in 20--
painoncology y8
Source
4
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
5
Drivers Challenges - Summary
Drivers
Challenges
Increasing patient population
Pricing pressure
Increasing number of vaccineapprovals
Logistic problems in the vaccinemarket
Increase in health insurancesIntroduction of new
drugs
5
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
6
Government Initiatives - Summary
Changes in tax structure
Control programmes
Government
Initiatives
PPP Projects
Reduction in drug prices
6
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
7
Major domestic players in the market (1/9)
Company Snapshot Company 1
Corporate Information
Financial Performance
Revenue Revenue ProfitINR bn INR bn
Headquarters Location A
Profit / Loss
r4 60
Founded 19--
100
r3
r1 r2
40
Products Product 1, product 2
50
20
Key People Person X- MD
0
0
2008 2009
2010 2011
Business Highlights
Employing around XX people, Company 1 is
Indias largest pharmaceutical company, having
manufacturing facilities inseven countries and
serving customers in over YY countries
In June 20--, the company entered into an
alliance with Company X to create an innovator
and genericpharmaceuticals powerhouse
Company 1 launched anti-infectives such as
Product 1 and Product 2 for the first time in
India and is trying to promotethe concept of
product 3 on a local basis
Signed an agreement with Company X for
manufacturing and marketing 3 new HIV/AIDS drugs
in India anddeveloping countries
Has been working on an anti-malaria research
project since May 20-- to develop cheap anti
malarial drugs
Source
7
ANTI-INFECTIVE PHARMACEUTICAL MARKET INDIA
2011.PPT
8
For more details about the report visit
http//www.bharatbook.com/medical-devices-market-r
esearch-reports/adonis-medical-systems-pvt-ltd-com
pany-profile-2011.html
http//www.bharatbook.com/healthcare-market-resear
ch-reports/anti-infective-pharmaceuticals-market-i
n-india-2012.html
Bharat Book Bureau Phone 91 22 27810772,
27810773 Fax 91 22 27812290 E-mail
info_at_bharatbook.com Website www.bharatbook.com
Write a Comment
User Comments (0)